Skip to main content
Premium Trial:

Request an Annual Quote

Eurogentec Hooks Scorpions Tech from DxS

NEW YORK, Jan. 21 - UK-based pharmacogenomics firm DxS has granted non-exclusive rights to its Scorpions genotyping technology to Eurogentec, according to Eurogentec.

Terms of the agreement call for Eurogentec, of Liège, Belgium, to acquire non-exclusive rights to manufacture and supply the technology to the life-science community, excluding agrochemical firms, the company said in a statement.

DxS receives an undisclosed royalty in exchange. Further financial details of the deal remained undisclosed.

The Scorpions technology "involves a single, instant reaction and avoids competing and/or side reactions" and can process up to 100,000 assays per day, according to DxS.

"We are delighted to have concluded this, our first licensing agreement, with a strong, international provider of genomic research solutions," Steve Little, CEO of DxS, said in a statement in released in early January.

Eurogentec, which markets a range of genomic- and proteomic-based tools and technologies, was founded in 1985 as a spin-off of the University of Liège. It has subsidiaries in France, Germany, the UK, the Netherlands, and a branch office in Switzerland.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.